OLD National Bancorp IN Has $384,000 Stock Position in GSK plc (NYSE:GSK)

OLD National Bancorp IN cut its holdings in GSK plc (NYSE:GSK) by 16.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,350 shares of the pharmaceutical company’s stock after selling 2,000 shares during the quarter. OLD National Bancorp IN’s holdings in GSK were worth $384,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. FMR LLC raised its position in shares of GSK by 7.7% during the third quarter. FMR LLC now owns 18,099,513 shares of the pharmaceutical company’s stock worth $656,107,000 after acquiring an additional 1,291,161 shares during the last quarter. Kahn Brothers Group Inc. bought a new stake in GSK in the third quarter worth approximately $46,483,000. Adage Capital Partners GP L.L.C. bought a new stake in GSK in the third quarter worth approximately $45,114,000. Morningstar Investment Services LLC increased its holdings in GSK by 1,684.1% in the third quarter. Morningstar Investment Services LLC now owns 1,136,495 shares of the pharmaceutical company’s stock worth $41,300,000 after purchasing an additional 1,072,792 shares in the last quarter. Finally, Hudson Bay Capital Management LP bought a new stake in GSK in the third quarter worth approximately $25,625,000. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Stock Performance

Shares of GSK opened at $40.88 on Thursday. The firm has a market cap of $84.72 billion, a PE ratio of 13.58, a PEG ratio of 1.45 and a beta of 0.64. The stock’s fifty day moving average price is $41.86 and its two-hundred day moving average price is $38.91. The company has a debt-to-equity ratio of 1.19, a current ratio of 0.88 and a quick ratio of 0.62. GSK plc has a 1 year low of $33.33 and a 1 year high of $43.84.

GSK (NYSE:GSK) last issued its earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.04). The firm had revenue of $10 billion during the quarter, compared to the consensus estimate of $9.79 billion. GSK had a net margin of 16.24% and a return on equity of 51.45%. On average, equities research analysts forecast that GSK plc will post 4.03 EPS for the current year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, April 11th. Shareholders of record on Friday, February 23rd were paid a $0.3564 dividend. The ex-dividend date of this dividend was Thursday, February 22nd. This is a positive change from GSK’s previous quarterly dividend of $0.34. This represents a $1.43 annualized dividend and a dividend yield of 3.49%. GSK’s payout ratio is presently 52.82%.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on GSK. Morgan Stanley began coverage on GSK in a report on Tuesday, January 23rd. They set an “equal weight” rating for the company. Guggenheim raised GSK from a “neutral” rating to a “buy” rating in a research report on Monday, March 4th. Jefferies Financial Group raised GSK from a “hold” rating to a “buy” rating in a research report on Wednesday, January 3rd. Finally, Citigroup raised GSK from a “neutral” rating to a “buy” rating in a research report on Tuesday, February 13th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.